

Mohammed Bahey-El-Din

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8836169/publications.pdf>

Version: 2024-02-01

30
papers

684
citations

471371

17
h-index

552653

26
g-index

30
all docs

30
docs citations

30
times ranked

931
citing authors

#	ARTICLE	IF	CITATIONS
1	Plant DNA barcoding and metabolomics for comprehensive discrimination of German Chamomile from its poisonous adulterants for food safety. <i>Food Control</i> , 2022, 136, 108840.	2.8	8
2	Bacterial Ghosts of <i>Pseudomonas aeruginosa</i> as a Promising Candidate Vaccine and Its Application in Diabetic Rats. <i>Vaccines</i> , 2022, 10, 910.	2.1	2
3	Recombinant Ax21 protein is a promising subunit vaccine candidate against <i>Stenotrophomonas maltophilia</i> in a murine infection model. <i>Vaccine</i> , 2021, 39, 4471-4480.	1.7	3
4	Immunization with the basic membrane protein (BMP) family ABC transporter elicits protection against <i>Enterococcus faecium</i> in a murine infection model. <i>Microbes and Infection</i> , 2020, 22, 127-136.	1.0	2
5	Recombinant N-terminal outer membrane porin (OprF) of <i>Pseudomonas aeruginosa</i> is a promising vaccine candidate against both <i>P. aeruginosa</i> and some strains of <i>Acinetobacter baumannii</i> . <i>International Journal of Medical Microbiology</i> , 2020, 310, 151415.	1.5	26
6	Vancomycin-functionalized Eudragit-based nanofibers: Tunable drug release and wound healing efficacy. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 58, 101812.	1.4	12
7	Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs nano-hybrids: covalent coupling and phospholipid complexation approaches. <i>Journal of Nanobiotechnology</i> , 2019, 17, 7.	4.2	36
8	Immunization with the ferric iron-binding periplasmic protein HitA provides protection against <i>Pseudomonas aeruginosa</i> in the murine infection model. <i>Microbial Pathogenesis</i> , 2019, 131, 181-185.	1.3	18
9	Enhanced transdermal permeability of Terbinafine through novel nanoemulgel formulation; Development, in vitro and in vivo characterization. <i>Future Journal of Pharmaceutical Sciences</i> , 2018, 4, 18-28.	1.1	58
10	Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against <i>Klebsiella pneumoniae</i> in the murine infection model. <i>Microbial Pathogenesis</i> , 2018, 119, 12-18.	1.3	22
11	Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. <i>Nanomedicine</i> , 2018, 13, 2637-2656.	1.7	63
12	Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging. <i>Nanomedicine</i> , 2018, 13, 1707-1730.	1.7	30
13	<i>Mycobacterium tuberculosis</i> Mycothiol acetyltransferase (Rv0819) is a potential biomarker for direct diagnosis of tuberculosis using patient serum specimens. <i>Letters in Applied Microbiology</i> , 2017, 65, 504-511.	1.0	3
14	Novel lecithin-integrated liquid crystalline nanogels for enhanced cutaneous targeting of terconazole: development, in vitro and in vivo studies. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5531-5547.	3.3	42
15	<i>Listeria monocytogenes</i> mutants defective in gallbladder replication represent safety-enhanced vaccine delivery platforms. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2059-2063.	1.4	10
16	Recombinant expression of the alternate reading frame protein (ARFP) of hepatitis C virus genotype 4a (HCV-4a) and detection of ARFP and anti-ARFP antibodies in HCV-infected patients. <i>Archives of Virology</i> , 2015, 160, 1939-1952.	0.9	10
17	Successful detection, expression and purification of the alternatively spliced truncated Sm14 antigen of an Egyptian strain of <i>Schistosoma mansoni</i> . <i>Journal of Helminthology</i> , 2015, 89, 764-768.	0.4	2
18	Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against <i>Schistosoma mansoni</i> in murine infection model. <i>BMC Infectious Diseases</i> , 2015, 15, 147.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Two-tiered biological containment strategy for <i>Lactococcus lactis</i> -based vaccine or immunotherapy vectors. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 333-337.	1.4	3
20	Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental <i>Schistosoma mansoni</i> infection. <i>Experimental Parasitology</i> , 2014, 145, 51-60.	0.5	20
21	Vaccination Studies: Detection of a <i>Listeria monocytogenes</i> -Specific T Cell Immune Response Using the ELISPOT Technique. <i>Methods in Molecular Biology</i> , 2014, 1157, 263-274.	0.4	1
22	A mutant in the <i>Listeria monocytogenes</i> Fur-regulated virulence locus (<i>frvA</i>) induces cellular immunity and confers protection against listeriosis in mice. <i>Journal of Medical Microbiology</i> , 2013, 62, 185-190.	0.7	19
23	<i>Lactococcus lactis</i> -based vaccines from laboratory bench to human use: An overview. <i>Vaccine</i> , 2012, 30, 685-690.	1.7	56
24	<i>Lactococcus lactis</i> -based vaccines: Current status and future perspectives. <i>Hum Vaccin</i> , 2011, 7, 106-109.	2.4	23
25	<i>Lactococcus lactis</i> as a Cell Factory for Delivery of Therapeutic Proteins. <i>Current Gene Therapy</i> , 2010, 10, 34-45.	0.9	56
26	Expression of two <i>Listeria monocytogenes</i> antigens (P60 and LLO) in <i>Lactococcus lactis</i> and examination for use as live vaccine vectors. <i>Journal of Medical Microbiology</i> , 2010, 59, 904-912.	0.7	23
27	Efficacy of a <i>Lactococcus lactis</i> <i>pyrG</i> vaccine delivery platform expressing chromosomally integrated <i>hly</i> from <i>Listeria monocytogenes</i> . <i>Bioengineered Bugs</i> , 2010, 1, 66-74.	2.0	27
28	<i>Lactococcus lactis</i> : from the dairy industry to antigen and therapeutic protein delivery. <i>Discovery Medicine</i> , 2010, 9, 455-61.	0.5	12
29	Nisin inducible production of listeriolysin O in <i>Lactococcus lactis</i> NZ9000. <i>Microbial Cell Factories</i> , 2008, 7, 24.	1.9	27
30	<i>Lactococcus lactis</i> -expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against <i>Listeria monocytogenes</i> in the murine infection model. <i>Vaccine</i> , 2008, 26, 5304-5314.	1.7	47